Skip to main content

Table 2 Univariate Cox proportional hazards regression analysis for overall survival and relapse-free survival in gallbladder carcinoma patients

From: Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma

CharacteristicsNo.OSpRFSp
HR (95% CI)HR (95% CI)
Age, y ≥ 65 (vs. <  65)50/1052.720 (1.655–4.470)<  0.0012.600 (1.592–4.245)<  0.001
Sex, female (vs. male)50/1050.853 (0.529–1.376)0.5160.796 (0.495–1.280)0.347
CEA, elevated (vs. normal)19/1051.284 (0.701–2.352)0.4191.194 (0.653–2.185)0.564
CA19–9, elevated (vs. normal)34/1051.864 (1.143–3.040)0.0131.809 (1.112–2.942)0.017
TNM stage
 I25/1051<  0.0011<  0.001
 II37/1052.459 (1.094–5.529)0.0302.619 (1.170–5.862)0.019
 III31/1055.495 (2.466–12.247)<  0.0015.129 (2.300–11.436)<  0.001
 IV12/10518.262 (6.941–48.048)<  0.00116.700 (6.374–43.750)<  0.001
T category
 T126/1051<  0.0011<  0.001
 T250/1052.954 (1.358–6.425)0.0063.051 (1.406–6.622)0.005
 T325/10510.560 (4.641–24.030)<  0.0019.672 (4.252–22.004)<  0.001
 T44/10511.670 (3.379–40.309)<  0.00112.256 (3.542–42.413)<  0.001
LN metastasis, presence (vs. absence)26/1052.019 (1.207–3.376)0.0071.898 (1.137–3.168)0.014
Distant metastasis, presence (vs. absence)7/1057.082 (2.971–16.885)<  0.0015.419 (2.339–12.555)<  0.001
Lymphovascular invasion, presence (vs. absence)10/1053.166 (1.551–6.465)0.0022.886 (1.416–5.881)0.004
Histologic type
 adenocarcinoma NOS101/10510.00310.005
 adenosquamous carcinoma3/1054.268 (1.320–13.800)0.0153.587 (1.113–11.563)0.032
 squamous cell carcinoma NOS1/10515.503 (1.903–126.302)0.01015.437 (1.894–125.789)0.011
Histologic grade, high (vs. low)62/1053.197 (1.855–5.510)<  0.0012.989 (1.753–5.097)<  0.001
cytoplasmic ZNF16, positive (vs. negative)40/1051.675 (1.038–2.703)0.0351.557 (0.968–2.505)0.068
nuclear ZNF16, positive (vs. negative)60/1053.287 (1.888–5.722)<  0.0013.038 (1.765–5.229)<  0.001
cytoplasmic FAM83H, positive (vs. negative)34/1052.292 (1.413–3.720)<  0.0012.201 (1.360–3.564)0.001
nuclear FAM83H, positive (vs. negative)49/1052.823 (1.716–4.646)<  0.0012.685 (1.640–4.395)<  0.001
  1. Abbreviations: OS overall survival, RFS relapse-free survival, HR hazard ratio, 95% CI 95% confidence interval, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, LN lymph node, NOS not otherwise specified